FDA to Postpone Enforcement Against AbbVie's Armour Thyroid Ahead of BLA Transition
FDA Shifts from Immediate Withdrawal to Conditional Management
The U.S. Food and Drug Administration (FDA) announced that it will continue to enforce risk-based regulations on unapproved animal-derived thyroid (ADT) products until March 11, 2026, and will provide guidance on compliance priorities by August 2026. This represents a shift from the previously announced plan in August 2025, which allowed for a maximum of 12 months for patient transition, prioritizing continuity of treatment. However, the FDA clarified that this is not a complete withdrawal of enforcement and that it will take action against companies that violate quality standards or put patients at risk, meaning that manufacturing management burdens will remain. This announcement is not an approval or an advisory committee (AdComm) vote; a Biologics License Application (BLA) is required to continue marketing the product.
Armour and NP are T4/T3 Combination Biological Products
AbbVie's (ABBV) Armour Thyroid (porcine-derived desiccated thyroid extract) and Acella Pharmaceuticals' NP Thyroid (thyroid tablets USP) are thyroid hormone replacement therapies that supplement thyroxine (T4) and triiodothyronine (T3) for the treatment of hypothyroidism. Both products have been marketed for a long time but have not undergone FDA safety and efficacy reviews for approval. Currently, they are categorized as unapproved marketed products and are in the BLA development stage. The FDA considers these products to be biologics due to their derivation from animal tissues and the presence of thyroglobulin and other complex components. Therefore, pharmacies and outsourcing facilities cannot apply the compounding exceptions under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Clinical Development is Key to Market Retention
AbbVie is conducting an ongoing Phase 2/3 clinical trial (NCT06345339) comparing Armour Thyroid with synthetic T4 in adult patients with primary hypothyroidism. This trial aims to evaluate the efficacy and safety of switching patients stabilized on synthetic T4 to Armour Thyroid, and will serve as the basis for future BLA submissions. Acella, through its affiliate Neuvosyn Laboratories, is developing a new DTE (desiccated thyroid extract) using the same active ingredient as NP Thyroid and has reportedly completed a Phase 2 study by 2025. Whether these products meet the required clinical and Chemistry, Manufacturing, and Controls (CMC) standards outlined in the regulatory guidance will determine their survival in the market.
A $24 Million Prescription Market May Be Reorganized
According to FDA data, in 2024, approximately 24 million patients in the U.S. received thyroid hormone replacement therapy, with 94% (approximately 22 million) receiving synthetic levothyroxine and 6% (1.5 million) receiving unapproved ADT. The North American hypothyroidism drug market was valued at USD 3.2 billion in 2024, and is characterized by a large volume of prescriptions and a high demand for repeat use. The standard treatment is levothyroxine, which targets T4 supplementation, and key competitors include Synthroid, Levoxyl, Unithroid, and Tirosint, as well as generic versions. Synthroid received NDA approval in 2002 as part of the FDA's levothyroxine quality review process, and the FDA and professional societies recommend synthetic levothyroxine as the preferred treatment.
Quality Issues and Insurance Coverage Will Determine Commercial Success
The FDA has cited over 500 adverse event reports related to ADT from 1968 to February 2025, as well as cGMP violations and recalls due to under- or over-potency in manufacturing facilities since 2017, as the basis for regulatory action. Given the narrow therapeutic index, variations in T3 and T4 levels between batches can lead to hyperthyroidism or inadequate treatment, making the demonstration of manufacturing consistency crucial for BLA approval. CVS Caremark's decision to exclude DTE from its standard formulary starting in April 2026 indicates that prescription shifts may occur even before the FDA's final action. Conversely, successful BLA approval could convert the 1.5 million patients who prefer DTE into a legally approved market, providing Armour Thyroid and new DTE products with a differentiated commercial advantage.
In the short term, AbbVie (ABBV), Acella Pharmaceuticals, and Neuvosyn Laboratories have secured the opportunity to maintain supply until the FDA's August 2026 guidance. However, cGMP, CMC, and clinical costs, as well as pressure from Pharmacy Benefit Managers (PBMs) to exclude DTE from formularies, will continue. AbbVie's Armour Thyroid's ongoing Phase 2/3 NCT06345339 trial is critical to the value of its BLA, and Acella's new DTE requires subsequent development and the compilation of approval data following the completion of Phase 2. The competitive landscape is being reshaped between the 94% of U.S. patients in 2024 (approximately 22 million) who use approved levothyroxine and the 6% (1.5 million) who use unapproved ADT, with the North American market valued at USD 3.2 billion in 2024. In the medium to long term, products that successfully obtain BLA approval will be able to capture the DTE prescription base, while manufacturers that fail to do so will face patient shifts to Synthroid, Levoxyl, Unithroid, Tirosint, and generic versions, as well as reduced distribution.
Source: FDA Drug Approvals (rss)